OTC Drugs Office Take Two: FDA To Elevate Division Through CDER Revamp
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA proposal for Office of OTC Drug Products would oversee two divisions for monographed, NDA-approved products. Former home of OTC division, ODE V, would be eliminated under CDER reorganization.